Page last updated: 2024-11-11

6 beta-hydroxycortisol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6 beta-hydroxycortisol: RN given refers to the (6beta,11beta)-isomer; see also record for 6 alpha-hydrocortisol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6beta-hydroxycortisol : A C21-steroid that is cortisol bearing an additional hydroxy substituent at the 6beta-position. In humans, it is produced as a metabolite of cortisol by cytochrome p450-3A4 (CYP3A4, an important enzyme involved in the metabolism of a variety of exogenous and endogenous compounds) and can be used to detect moderate and potent CYP3A4 inhibition in vivo. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6852390
CHEMBL ID1389133
CHEBI ID139271
SCHEMBL ID142686
MeSH IDM0041539

Synonyms (44)

Synonym
MLS000028854 ,
smr000058916
6beta-hydroxycortisol
nsc-76163
6,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one
nsc76163
53-35-0
6 beta-hydroxycortisol
CHEBI:139271
6beta,11beta,17,21-tetrahydroxypregn-4-ene-3,20-dione
(6beta,11beta)-6,11,17,21-tetrahydroxypregn-4-ene-3,20-dione
6beta-oh-cortisol
6beta-ho-cortisol
nsc 76163
6|a-hydroxy prednisolone
(6r,8s,9s,10r,11s,13s,14s,17r)-6,11,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one
NCGC00247037-01
HMS2235P15
corticosterone, 6beta,17-dihydroxy-
pregn-4-ene-3,20-dione, 6beta,11beta,17,21-tetrahydroxy-
pregn-4-en-3,20-dione, 6,11,17,21-tetrahydroxy-, (6beta,11beta)-
6beta,17-dihydroxycorticosterone
j37wkj5y50 ,
6,11beta,17,21-tetrahydroxypregn-4-ene-3,20-dione
unii-j37wkj5y50
6beta,11beta,17alpha,21-tetrahydroxypregn-4-en-3,20-dione
3078-34-0
6|a-hydroxycortisol
CHEMBL1389133
SCHEMBL142686
DTXSID80425873
OPERA_ID_751
AKOS027326842
6beta,11beta,17,21-tetrahydroxypregn-4-ene-3,20-dione (6beta-hydroxyhydrocortisone)
(6r,8s,9s,10r,11s,13s,14s,17r)-6,11,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
6beta-hydroxy cortisol
6.beta.-hydroxycortisol
6.beta.-hydroxyhydrocortisone
hydrocortisone impurity d [ep impurity]
6.beta.,11.beta.,17,21-tetrahydroxypregn-4-ene-3,20-dione
pregn-4-ene-3,20-dione, 6,11,17,21-tetrahydroxy-, (6.beta.,11.beta.)-
Q63393460
6-beta-hydroxycortisol
benzyl 2-acetamido-2-deoxy-4-o- beta -d-galactofuranosyl- alpha -d-glucopyranoside

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events reported in the multiple dose treatment with S-3304 or placebo were mostly of mild severity, except for two episodes of moderate headache and two episodes of moderate myalgia."( Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.
Kambayashi, Y; Sollie, F; van Marle, S; van Vliet, A; Yamada-Sawada, T, 2005
)
0.33
" There was no increase in adverse events observed for bevirimat compared with placebo, and no serious adverse events occurred."( Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Ballow, C; Blum, R; Doto, J; Galbraith, H; Martin, DE, 2007
)
0.34
" Administration of macitentan was safe and well tolerated."( Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
Dingemanse, J; Sidharta, PN; van Giersbergen, PL, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" In order to determine the endoplasmatic reticulum enzyme function, 6-beta-hydroxycortisol excretion and antipyrine pharmacokinetic parameters were evaluated."( Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam.
Brockmeyer, NH; Goos, M; Klimek, K; Mertins, L; Ohnhaus, EE, 1990
)
0.28
" The metabolic clearance rate (MCR) and plasma half-life of this material were measured before and after 6 days of rifampicin treatment (600 mg/day) in seven patients with Addison's disease due to tuberculosis."( Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism.
Benker, G; Mönig, H; Ohnhaus, EE; Pagel, H; Reinwein, D; Schulte, HM, 1987
)
0.27
"h/liter) and the terminal half-life of fleroxacin (11."( Influence of rifampin on fleroxacin pharmacokinetics.
Dayer, P; Leemann, T; Lew, DP; Portmann, R; Schrenzel, J; Weidekamm, E, 1993
)
0.29
" Respective changes were seen with regard to the area under the EE2 serum concentration curve up to 4 and 24 hours (AUC0-4 and AUC0-24), cmax and tmax of serum EE2."( Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Back, DJ; Daume, E; Hammerstein, J; Neiss, A; Schindler, AE; Simon, A; Ward, S; Winkler, UH, 1993
)
0.48
" No significant differences were seen in serum EE2 levels including the rise in mean EE2 on days 1-10, or the smaller rise between days 10-21, or the pharmacokinetic parameters Cmax, tmax, area under the curve (AUC) at 0-4 hours, or AUC at 0-24 hours."( Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
Back, DJ; Daume, E; Hammerstein, J; Neiss, A; Schindler, AE; Simon, A; Ward, S; Winkler, UH, 1993
)
0.48
" Reboxetine pharmacokinetic parameters, calculated after the single dose using non-compartmental analysis, were in good agreement with those obtained in previous studies."( Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations.
Edwards, DM; Jørgensen, NP; Paus, E; Pellizzoni, C; Poggesi, I; Strolin Benedetti, M, 1996
)
0.29
" In order to determine the microsomal enzyme activity, the 6-beta-hydroxycortisol/17-hydroxycorticosteroid ratio and antipyrine pharmacokinetic parameters were determined."( Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
Barthel, B; Brockmeyer, NH; Goos, M; Mertins, L; Tillmann, I, 1997
)
0.3
"16) in delavirdine pharmacokinetic parameters between treatment groups on day 15 or day 30."( Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.
Anderson, RD; Borin, MT; Carel, BJ; Cox, SR; Freimuth, WW; Herman, BD, 1997
)
0.3
" The purpose of the present study was to assess the potential for a pharmacokinetic interaction between olanzapine and carbamazepine, since these agents are likely to be used concomitantly in the treatment of manic psychotic disorder."( A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
Bergstrom, RF; Gilfillan, DJ; Lucas, RA, 1998
)
0.3
" Olanzapine pharmacokinetic values for Cmax and AUC were significantly lower after the second dose, the elimination half-life was significantly shorter, and the clearance and volume of distribution were significantly increased."( A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
Bergstrom, RF; Gilfillan, DJ; Lucas, RA, 1998
)
0.3
"Forty-two healthy subjects were randomized in a parallel three-group design trial to investigate potential electrocardiographic and pharmacokinetic interactions between the new antimalarial co-artemether, a combination of artemether and lumefantrine (both of which are predominantly metabolized through CYP3A4), and mefloquine, another antimalarial described as a substrate (and possible inhibitor) of CYP3A4."( Pharmacokinetic interaction trial between co-artemether and mefloquine.
Bindschedler, M; Ezzet, F; Lefèvre, G; Meyer, I; Schaeffer, N; Thomsen, MS, 2000
)
0.31
"Mean (+/-SD) values of peak plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve [AUC(0-48)] and elimination half-life (tl/2) of alprazolam were 12."( No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam.
Chiba, K; Kaneko, S; Kondo, T; Kubota, T; Nagasaki, T; Ohkubo, T; Otake, H; Otani, K; Sugawara, K; Yasui-Furukori, N, 2001
)
0.31
" Everolimus half-life was reduced significantly, from an average of 32 hours to 24 hours."( Effect of rifampin on apparent clearance of everolimus.
Figueiredo, J; Hartmann, S; Kovarik, JM; Port, A; Rordorf, C; Rouilly, M, 2002
)
0.31
" This study was designed to assess whether the application of our method to individualized dosing could decrease pharmacokinetic (PK) and pharmacodynamic (PD) variability compared with body-surface area (BSA) -based dosing."( Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
Ishizuka, N; Kodama, T; Kunitoh, H; Murakami, H; Nishio, K; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimizu, M; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N, 2005
)
0.33
" Pharmacokinetic parameters were determined for S-3304 and its metabolites."( Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.
Kambayashi, Y; Sollie, F; van Marle, S; van Vliet, A; Yamada-Sawada, T, 2005
)
0.33
" An open-label, 2-period, nonrandomized, phase-I, pharmacokinetic interaction design was used."( Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial.
Calvo, A; Martínez, I; Portolés, A; Resplandy, G; Terleira, A, 2006
)
0.33
" PHARMACOKINETIC AND STATISTICAL ANALYSIS: Plasma bevirimat levels were measured from blood samples collected pre-dose on days 1-10 and then at approximately 48-hour intervals until 21 days after dosing started."( Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Ballow, C; Blum, R; Doto, J; Galbraith, H; Martin, DE, 2007
)
0.34
"The mean terminal elimination half-life of bevirimat ranged from 56."( Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Ballow, C; Blum, R; Doto, J; Galbraith, H; Martin, DE, 2007
)
0.34
"The pharmacokinetic parameters of diazepam and one of its metabolites, N-demethyldiazepam, were compared after oral administration of diazepam (10 mg) in the absence or presence of oral GBE (120 mg bid, for 28 days) in 12 healthy volunteers."( Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects.
Chen, BM; Dai, LL; Jia, SJ; Li, J; Liu, SK; Yang, GP; Yuan, H; Zhang, BK; Zhang, J; Zhou, LY; Zuo, XC, 2010
)
0.36
"The 90% confidence intervals (CIs) of the ratios of mean pharmacokinetic parameters of diazepam presence and absence of GBE were well within the 80-125% bioequivalence range, indicating no pharmacokinetic interaction."( Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects.
Chen, BM; Dai, LL; Jia, SJ; Li, J; Liu, SK; Yang, GP; Yuan, H; Zhang, BK; Zhang, J; Zhou, LY; Zuo, XC, 2010
)
0.36
"4) in the maximum plasma concentration (C(max)), area under the concentration-time curve from time 0 to infinity (AUC(0-∞)), and terminal half-life (t(1/2)), respectively, of midazolam; the time to peak plasma concentration (t(max)) was unchanged."( Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Alessi, F; Dingemanse, J; Hoch, M; Hoever, P; Theodor, R, 2013
)
0.39
" Pharmacokinetic simulation suggested in vivo relevance of CYP3A4 inhibition by DX-619."( Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects.
Imamura, Y; Inoue, K; Izumi, T; Kurihara, A; Kusuhara, H; Murayama, N; Okudaira, N; Sugiyama, Y; Yuasa, H, 2013
)
0.39
" Several explanations have been suggested, including pharmacokinetic and pharmacogenomic variability."( Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).
Andreoli, R; Ardizzoni, A; Azzoni, C; Bartolotti, M; Bortesi, B; De Palma, G; Gelsomino, F; Goldoni, M; Mozzoni, P; Mutti, A; Silini, EM; Tiseo, M, 2014
)
0.4
"These findings suggest that the pharmacokinetics and metabolism of erlotinib are related to skin toxicity and may support further studies where erlotinib dosing is tailored according to pharmacokinetic parameters."( Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).
Andreoli, R; Ardizzoni, A; Azzoni, C; Bartolotti, M; Bortesi, B; De Palma, G; Gelsomino, F; Goldoni, M; Mozzoni, P; Mutti, A; Silini, EM; Tiseo, M, 2014
)
0.4
"Women receiving various ARVs had pharmacokinetic evaluations during the third trimester of pregnancy (>30 weeks) and postpartum with determination of 6βHF : F carried out on the same days."( Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.
Aweeka, FT; Best, BM; Burchett, SK; Capparelli, EV; Hu, C; Huang, L; Lizak, P; Mirochnick, M; Read, JS; Stek, A; Watts, H, 2015
)
0.42
"There were no significant correlations between the pharmacokinetic parameters of midazolam and urinary ratios of 6β-OHF/F."( Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Chan, SW; Chu, TT; Fok, BS; Hu, M; Lee, VH; Tomlinson, B; Xiao, Y; Yin, OQ, 2016
)
0.43
"There were no significant associations between midazolam pharmacokinetic parameters and urinary ratios of 6β-OHF/F and the two CYP3A polymorphisms were not associated with the urinary ratios of 6β-OHF/F or midazolam pharmacokinetic parameters."( Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Chan, SW; Chu, TT; Fok, BS; Hu, M; Lee, VH; Tomlinson, B; Xiao, Y; Yin, OQ, 2016
)
0.43
" The aim of the present study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of evogliptin in participants with renal impairment (RI)."( Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229).
Bahng, MY; Cho, H; Cho, JY; Jang, IJ; Kim, AH; Kim, YS; Lee, S; Oh, J; Yoon, SH; Yu, KS, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
" Based on previous studies, antipyrine given with phenobarbitone produced slightly more induction than phenobarbitone given alone."( Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man.
Gerber-Taras, E; Ohnhaus, EE; Park, BK, 1983
)
0.27
" A single dermal dose of DEET alone and in combination with permethrin significantly increased urinary excretion of 6beta-hydroxycortisol 24 h after dosing."( DEET (N,N-diethyl-m-toluamide) alone and in combination with permethrin increased urinary excretion of 6beta-hydroxycortisol in rats, a marker of hepatic CYP3A induction.
Abou-Donia, MB; Abu-Qare, AW, 2001
)
0.31
" 6β-OHF plasma concentration and the amount of 6β-OHF excreted into the urine (X(6β-OHF)) were measured in healthy subjects enrolled in drug-drug interaction studies of benzylpenicillin alone or with probenecid (study 1), adefovir alone or with probenecid (study 2), and metformin alone or with pyrimethamine (study 3)."( 6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects.
Damme, K; Heer, D; Imamura, Y; Izumi, T; Kumagai, Y; Kurihara, A; Kusuhara, H; Maeda, K; Murayama, N; Okudaira, N; Sugiyama, Y; Tsuruya, Y, 2014
)
0.4
" This midostaurin drug-drug interaction study assessed the dynamic response and clinical usefulness of urinary 6β-hydroxycortisol to cortisol ratio (6βCR) and plasma 4β-hydroxycholesterol (4βHC) for monitoring CYP3A4 activity in the presence or absence of rifampicin, a strong CYP3A4 inducer."( Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
Dutreix, C; Lorenzo, S; Wang, Y, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59."( The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
Back, DJ; Green, S; Orme, M; Ward, S, 1991
)
0.28
" The oral bioavailability of terguride over all doses was about 20%."( Pharmacokinetics and endocrine effects of terguride in healthy subjects.
Dorow, R; Gräf, KJ; Krause, W; Kühne, G; Sauerbrey, N; Träger, H, 1990
)
0.28
" Pharmacokinetic parameters indicate that the bioavailability of cyclosporin A was not significantly modified by ticlopidine."( A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients.
Barthelemy, JC; Batt, AM; Boissonnat, P; Brouard, R; de Lorgeril, M; Delaye, J; Perroux, V; Salen, P; Serres, E, 1997
)
0.3
"Cyclosporin bioavailability was not clearly modified by a half dosage of ticlopidine in this study."( A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients.
Barthelemy, JC; Batt, AM; Boissonnat, P; Brouard, R; de Lorgeril, M; Delaye, J; Perroux, V; Salen, P; Serres, E, 1997
)
0.3
"Because rifampicin may greatly decrease the oral bioavailability of nilvadipine, caution is needed when these two drugs are to be coadministered."( The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects.
Echizen, H; Fukuda, J; Furuie, K; Hayashi, T; Saima, S; Yoshimoto, H, 2002
)
0.31
" This enzyme induction most likely contributes to the decreased bioavailability observed upon co-administration of various drugs with Saint John's wort extract."( Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers.
Bauer, S; Brockmöller, J; Johne, A; Kerb, R; Roots, I; Störmer, E, 2002
)
0.31
" The increases in exposure were attributed to a change in bioavailability rather than a decrease in clearance."( The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive.
Martin, PD; Mitchell, PD; Schneck, DW; Simonson, SG; Warwick, MJ, 2004
)
0.32
"Nilotinib (Tasigna), an orally bioavailable second-generation BCR-ABL tyrosine kinase inhibitor, is approved for use in patients with chronic myeloid leukemia in chronic phase and accelerated phase who are resistant or intolerant to prior therapy, including imatinib."( Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.
Galitz, L; Grouss, K; Harrell, R; Schran, H; Sethuraman, V; Smith, T; Tanaka, C; Yin, OQ, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" In the same subjects, rifabutin in the proposed therapeutic dosage (300 mg daily) for 7 days also enhanced the metabolic elimination of antipyrine, with preferential stimulation of the demethylation pathway, and increased the excretion of 6-beta-hydroxycortisol, but the magnitude of the effects was significantly less than after rifampicin."( Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects.
Frigo, GM; Grimaldi, R; Mönig, H; Ohnhaus, EE; Perucca, E; Sardi, A, 1988
)
0.27
" Cortisol hydroxylation was increased in the group of epileptics with large inter-individual variations notwithstanding a similar dosage of inducers."( Urinary 6-beta-OH-cortisol and paracetamol metabolites as a probe for assessing oxidation and conjugation of chemicals in humans.
Dolara, P; Lodovici, M; Muscas, GC; Salvadori, M; Zaccara, G, 1987
)
0.27
" Cytochrome P-450 1A2 activity was monitored by means of the 13C-[N3-methyl]caffeine breath test and by means of plasma caffeine clearance before omeprazole treatment with 120 mg/day, on the seventh day of dosage and after a 7-day washout."( Specific and dose-dependent enzyme induction by omeprazole in human beings.
Brösicke, H; Heinemeyer, G; Roots, I; Rost, KL, 1994
)
0.29
" The dosing regimen was well tolerated by all subjects."( Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations.
Edwards, DM; Jørgensen, NP; Paus, E; Pellizzoni, C; Poggesi, I; Strolin Benedetti, M, 1996
)
0.29
" There is no evidence that the dosage of drugs metabolized by the CYP3A4 isoenzyme needs to be adjusted for disease activity in RA."( Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis.
Beyeler, C; Bird, HA; Frey, BM, 1997
)
0.73
" Harvested plasma from serial blood samples collected after dosing on days 15, 16, and 30 was assayed for delavirdine and its N-desalkyl metabolite concentrations with a reversed-phase HPLC method."( Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
Borin, MT; Carel, BJ; Chambers, JH; Freimuth, WW; Gagnon, S, 1997
)
0.3
"09 mumol/L) steady-state through drug concentrations in all patients after 2 weeks of concurrent dosing of delavirdine mesylate and rifampin."( Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
Borin, MT; Carel, BJ; Chambers, JH; Freimuth, WW; Gagnon, S, 1997
)
0.3
"Cyclosporin bioavailability was not clearly modified by a half dosage of ticlopidine in this study."( A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients.
Barthelemy, JC; Batt, AM; Boissonnat, P; Brouard, R; de Lorgeril, M; Delaye, J; Perroux, V; Salen, P; Serres, E, 1997
)
0.3
" A minimum of one steady state trough blood sample and one dosage interval urine were collected during days 3-6 and during days 7-14 post-injury."( Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury.
Adams, CA; Anderson, GD; Awan, AB; Temkin, NR; Winn, HR, 1998
)
0.3
" The results indicated elevations in the 6beta-OHF/F ratios that were dependent on both the dosing period and dose levels adopted."( Increase in urinary excretion of 6beta-hydroxycortisol in common marmosets as a marker of hepatic CYP3A induction.
Koyanagi, F; Manabe, S; Tanaka, K; Totsuka, S; Watanabe, T; Yasuda, M,
)
0.13
" On day 7, concentrations of verapamil and norverapamil enantiomers were determined during one dosing interval, and model independent pharmacokinetic parameters were estimated."( Effects of grapefruit juice and smoking on verapamil concentrations in steady state.
Fuhr, U; Harder, S; Jünemann, M; Kern, R; Lopez-Rojas, P; Müller-Peltzer, H; Staib, AH, 2002
)
0.31
" This may warrant dosage adjustment during pregnancy."( Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.
Aweeka, FT; Beckerman, KP; Hayashi, S; Homma, M; Kosel, BW, 2003
)
0.32
" This study was designed to assess whether the application of our method to individualized dosing could decrease pharmacokinetic (PK) and pharmacodynamic (PD) variability compared with body-surface area (BSA) -based dosing."( Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
Ishizuka, N; Kodama, T; Kunitoh, H; Murakami, H; Nishio, K; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimizu, M; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N, 2005
)
0.33
"The individualized dosing method based on the total amount of urinary 6-beta-OHF after cortisol administration can decrease PK variability of docetaxel."( Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
Ishizuka, N; Kodama, T; Kunitoh, H; Murakami, H; Nishio, K; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimizu, M; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N, 2005
)
0.33
" Subsequently blood and urine samples were collected after drug dosing as before."( Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
Adithan, C; Rajan, S; Shashindran, C; Tushar, T; Vinod, T, 2007
)
0.34
" This study was performed to investigate the pharmacokinetics and safety of bevirimat during repeated dosing in healthy volunteers."( Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Ballow, C; Blum, R; Doto, J; Galbraith, H; Martin, DE, 2007
)
0.34
" PHARMACOKINETIC AND STATISTICAL ANALYSIS: Plasma bevirimat levels were measured from blood samples collected pre-dose on days 1-10 and then at approximately 48-hour intervals until 21 days after dosing started."( Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Ballow, C; Blum, R; Doto, J; Galbraith, H; Martin, DE, 2007
)
0.34
" Testing for dose-proportionality showed that exposure to bevirimat was proportional to the dose, both after a single dose and after repeat dosing for 10 days."( Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Ballow, C; Blum, R; Doto, J; Galbraith, H; Martin, DE, 2007
)
0.34
"Bevirimat shows dose-proportional pharmacokinetics during repeated dosing for 10 days."( Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Ballow, C; Blum, R; Doto, J; Galbraith, H; Martin, DE, 2007
)
0.34
" These results indicate that concurrent use of strong CYP3A4 inducers or inhibitors may necessitate dosage adjustments of nilotinib and should be avoided when possible."( Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.
Galitz, L; Grouss, K; Harrell, R; Schran, H; Sethuraman, V; Smith, T; Tanaka, C; Yin, OQ, 2011
)
0.37
"This study investigated whether a single intra-articular administration (IA) of dexamethasone (DEX) in horses at therapeutic dosage could exert a systemic effect by influencing the hypothalamic-pituitary-adrenal axis activity as a consequence of (limited) absorption and systemic distribution."( Endocrine evaluation after an intra-articular therapeutic dosage of dexamethasone in horses.
Baia, F; Capolongo, F; Fidani, M; Gallina, G; Montesissa, C, 2013
)
0.39
"These findings suggest that the pharmacokinetics and metabolism of erlotinib are related to skin toxicity and may support further studies where erlotinib dosing is tailored according to pharmacokinetic parameters."( Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).
Andreoli, R; Ardizzoni, A; Azzoni, C; Bartolotti, M; Bortesi, B; De Palma, G; Gelsomino, F; Goldoni, M; Mozzoni, P; Mutti, A; Silini, EM; Tiseo, M, 2014
)
0.4
"The mean 6β-hydroxycortisol/cortisol ratio was reduced by 68% from baseline (P < 0·05) after the 1st pulse dosing, but the inhibitory effect appeared to be resolved before the next pulse dosing and at 3 months post-treatment."( Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis.
Atsuda, K; Echizen, H; Inamoto, N; Kubo, H; Machida, M; Ono, N; Saito, H; Shibata, S; Shinozaki, K; Takahashi, H; Wada, N, 2014
)
0.4
"6 for the three dosing groups (10, 20 and 100 mg)."( Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Andersson, TB; Bäckström, T; Bertilsson, L; Björkhem-Bergman, L; Bredberg, E; Diczfalusy, U; Nylén, H; Rönquist-Nii, Y, 2014
)
0.4
" We aimed to investigate if the combined ratio of endogenous 6β-hydroxycortisol and 6β-hydroxycortisone to cortisol and cortisone (HOM) in urine could be used as an endogenous probe for the prediction of cyclosporine dosage requirements in renal transplant recipients."( A non-invasive CYP3A4 biomarker and body mass index predict cyclosporine dosage requirements in Chinese renal transplant recipients.
Cai, N; Cheng, Z; Feng, H; Huang, X; Li, B; Luo, X; Xu, K; Zheng, L; Zhu, L, 2015
)
0.42
" Base on desired target range of tacrolimus trough concentrations, individual daily dosage regimen was calculated, and all the observed daily doses were within the predicted range."( Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients.
Cai, NF; Cheng, ZN; Luo, X; Zheng, LY; Zhu, LJ, 2016
)
0.43
"This study provides the equations to predict tacrolimus metabolism and dosage requirements based on the endogenous CYP3A4 phenotype, CYP3A5(*)3 genotype and other non-genetic variables."( Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients.
Cai, NF; Cheng, ZN; Luo, X; Zheng, LY; Zhu, LJ, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
mammalian metaboliteAny animal metabolite produced during a metabolic reaction in mammals.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
probeA role played by a molecular entity used to study the microscopic environment.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (9)

ClassDescription
C21-steroidA steroid that has a structure based on a 21-carbon (pregnane) skeleton. Note that individual examples may have ring substituents at other positions and/or contain double bonds, aromatic A-rings, expanded/contracted rings etc., so the formula and mass may vary from that given for the generic structure.
6beta-hydroxy steroidAny 6-hydroxy steroid in which the 6-hydroxy substituent has beta-configuration.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
21-hydroxy steroid
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
17alpha-hydroxy steroidThe alpha-stereoisomer of 17-hydroxy steroid.
11beta-hydroxy steroidAny 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
primary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency11.58210.004110.890331.5287AID504467
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.16230.035520.977089.1251AID504332
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency1.00000.010323.856763.0957AID2662
gemininHomo sapiens (human)Potency2.32700.004611.374133.4983AID624296; AID624297
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency23.93410.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID679578TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 uM, 6beta-hydroxycortisol: 100 uM) in Caco-2 cells1999Pharmaceutical research, Mar, Volume: 16, Issue:3
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
AID681354TP_TRANSPORTER: transepithelial transport in MDR1-expressing LLC-PK1 cells2003Pharmaceutical research, Nov, Volume: 20, Issue:11
Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (279)

TimeframeStudies, This Drug (%)All Drugs %
pre-199081 (29.03)18.7374
1990's64 (22.94)18.2507
2000's73 (26.16)29.6817
2010's53 (19.00)24.3611
2020's8 (2.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.20 (24.57)
Research Supply Index5.86 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials65 (22.73%)5.53%
Reviews13 (4.55%)6.00%
Case Studies2 (0.70%)4.05%
Observational0 (0.00%)0.25%
Other206 (72.03%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]